Continuous venous infusion 5-fluorouracil and interferon-α in pancreatic carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 2, 1998, Pages 147-150

  John, William J ^a   Flett, Melissa Q ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

5 Fluorouracil; Chemotherapy; Infusional; Interferon ; Pancreas

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PANCREAS CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING;

EID: 0031899236     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199804000-00011     Document Type: Article

References (29)

1. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott, 1993:849-82.
2. Kovach JS, Moertel CG, Schutt AJ, et al. A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974;33:563-7.
3. Hansen R, Quebbeman E, Ritch P, et al. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 1988;295:91-3.
4. Tajiri H, Yoshimori M, Okazaki N, et al. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 1991;8:18-21.
5. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985;53:2061-7.
6. Crown J, Casper ES, Botet J, et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.
7. Celle JP. Carcinoma of the pancreas. In: Sleisenger MH, Rordtran JS, eds. Gastrointestinal disease: pathophysiology, diagnosis, management. 4th ed. Philadelphia: WB Saunders, 1989:1872-84.
8. Cullinan SA, Moertel CG, Wieand HS, et al. A phase III trial of the therapy of advanced pancreatic carcinoma. Cancer 1990;65:2207-12.
9. Waddler S, Schwartz EL, Goldman M, et al. Fluorouracil in recombinant alpha-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
10. Kemeny N, Younes A. Alpha-2a interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial-Sloan Kettering experience. Semin Oncol 1992;19(Suppl):171-5.
11. Pazdur R, Moore DF, Bready B. Modulation of fluorouracil with recombinant alpha-interferon: MD Anderson Clinical Trial. Semin Oncol 1992;19(Suppl):176-9.
12. Weh HJ, Platz D, Braumann D, et al. Phase II trial of 5-fluorouracil in recombinant interferon-alpha-2b in metastatic colorectal carcinoma. Eur J Cancer 1992;28A:1820-3.
13. Diaz Rubio E, Yimeno J, Camps C, et al. Treatment of advanced colorectal cancer with recombinant interferon-alpha and fluorouracil: activity in liver metastases. Cancer Invest 1992;10:259-64.
14. Waddler S, Lembersky B, Atkins M, et al. Phase II trial of fluorouracil in recombinant interferon-alpha-2a in patients with colorectal carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1991;9:1806-10.
15. John WJ, Neefe JR, Macdonald JF, et al. 5-Fluorouracil and interferon-alpha-2a in advanced colorectal carcinoma: the results of two treatment schedules. Cancer 1993;72:3191-5.
16. Sparano JA, Waddler S, Diasio RB, et al. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alpha: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993;11:1609-17.
17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
18. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a MidAtlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
19. Rougier P, Zarba JJ, Ducreaux M, et al. Phase II study of cisplatin and 120 hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333-36.
20. Rothman H, Cantrell JE, Lokich J, et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: a Mid-Atlantic Oncology Program Study. Cancer 1991;68:264-8.
21. Isacoff WH, Reber H, Thompkins R, et al. Continuous infusion (CI) 5-fluorouracil (5-FU), calcium leucovorin (LV), mitomycin C (mito C) and dipyridamole (D); treatment for patients with locally advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:198.
22. Pazdur R, Ajani JA, Abbruzzese JL, et al. A phase II evaluation of fluorouracil and recombinant alpha-2a interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992;70:2073-6.
23. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon-alpha-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995;13:921-8.
24. York M, Grecco FA, Figlin RA, et al. A randomized phase III trial comparing 5-FU with or without interferon-alpha-2a for advanced colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1993;12:200.
25. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:199.
26. Buchler M, Sulkowski U, Pederzoli R, et al. A phase II study of octreotide (SMS) in advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol 1994;14:215.
27. Rosenberg L, Barkun AN, Denis MH, et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995;75:23-8.
28. Cascinu S, Del Ferro E, Catalano G. A randomized trial of octreotide versus best supportive care in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995;71:97-101.
29. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 1993;71:2200-3.